Disease · MONDO_0005477
Comparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 30
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ranolazine vs Placebo: Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First | 144 of 510 | 140 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients Whose First VT/VF Required Antitachycardia Pacing (ATP) | 92 of 510 | 117 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First. | 237 of 510 | 222 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With VT or VF Requiring ICD Shock or Death | 131 of 510 | 145 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Death | 70 of 510 | 78 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients Whose First VT/VF Required ICD Shock | 79 of 510 | 84 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death | 174 of 510 | 198 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: deaths from any cause | 70 of 510 | 78 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With First Inappropriate ICD Shock | 16 of 510 | 20 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: serious adverse events | 0 of 510 | 0 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Amiodarone Only vs Amiodarone + Catheter Ablation: Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest | 16 of 27 | 21 of 26 | 53 | NCT02301390 | Trial comparisons |
| Amiodarone Only vs Amiodarone + Catheter Ablation: deaths from any cause | 2 of 27 | 2 of 26 | 53 | NCT02301390 | Trial comparisons |
| Amiodarone Only vs Amiodarone + Catheter Ablation: serious adverse events | 11 of 27 | 8 of 26 | 53 | NCT02301390 | Trial comparisons |
| Dantrolene/Ryanodex vs Placebo: Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol. | 4 of 29 | 9 of 22 | 51 | NCT04134845 | Trial comparisons |
| Dantrolene/Ryanodex vs Placebo: deaths from any cause | 0 of 29 | 0 of 22 | 51 | NCT04134845 | Trial comparisons |
| Dantrolene/Ryanodex vs Placebo: serious adverse events | 0 of 29 | 0 of 22 | 51 | NCT04134845 | Trial comparisons |
| Flecainide vs Placebo: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT03685149 | Trial comparisons |
| Flecainide vs Placebo: serious adverse events | 1 of 22 | 1 of 22 | 44 | NCT03685149 | Trial comparisons |
| Flecainide vs Placebo: Number of Participants With Proarrhythmic Response to Flecainide | 3 of 19 | 3 of 19 | 38 | NCT03685149 | Trial comparisons |
| Catheter Ablation vs Antiarrhythmic Medication: serious adverse events | 6 of 13 | 7 of 14 | 27 | NCT01576042 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005477/comparisons